Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

 

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 1, 2012

Commission file number 0-7647

 

HAWKINS, INC.

(Exact name of registrant as specified in its charter)

 

MINNESOTA		41-0771293
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

3100 EAST HENNEPIN AVENUE, MINNEAPOLIS, MINNESOTA 55413

(Address of principal executive offices, including zip code)

(612) 331-6910

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.  YES  ý    NO  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  YES  ý    NO  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large Accelerated Filer  ¨    Accelerated Filer  ý    Non-Accelerated Filer  ¨    Smaller Reporting Company  ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

                YES   ¨    NO  ý

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

CLASS		OUTSTANDING AT JANUARY 31, 2012
Common Stock, par value $.05 per share		10,428,296

 

 

 

 

1

 

 

---

Table of Contents

HAWKINS, INC.

INDEX TO FORM 10-Q

 

 

				Page
PART I.		FINANCIAL INFORMATION
Item 1.		Financial Statements (unaudited):
		Condensed Consolidated Balance Sheets – January 1, 2012 and April 3, 2011		3
		Condensed Consolidated Statements of Income – Three and Nine Months Ended January 1, 2012 and December 31, 2010		4
		Condensed Consolidated Statements of Cash Flows –Nine Months Ended January 1, 2012 and December 31, 2010		5
		Notes to Condensed Consolidated Financial Statements		6
Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations		12
Item 3.		Quantitative and Qualitative Disclosures about Market Risk		16
Item 4.		Controls and Procedures		17
PART II.		OTHER INFORMATION
Item 1.		Legal Proceedings		17
Item 1A.		Risk Factors		17
Item 6.		Exhibits		18
Signatures				18
Exhibit Index				19

 

2

 

 

---

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

HAWKINS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

 

		January 1, 2012				April 3, 2011
		(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	19,280			$	18,940
Investments available-for-sale			10,971				15,286
Trade receivables - less allowance for doubtful accounts:
$435 as of January 1, 2012 and $406 as of April 3, 2011			35,381				35,736
Inventories			32,367				29,217
Income taxes receivable			-				2,197
Prepaid expenses and other current assets			2,394				2,872
Total current assets			100,393				104,248
PROPERTY, PLANT, AND EQUIPMENT - net			69,900				62,395
GOODWILL			6,495				6,231
INTANGIBLE ASSETS			8,341				8,811
LONG-TERM INVESTMENTS			6,365				3,175
OTHER			161				145
		$	191,655			$	185,005
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable – trade		$	15,676			$	23,350
Dividends payable			-				3,095
Accrued payroll and employee benefits			6,838				7,760
Deferred income taxes			2,620				2,619
Container deposits			1,053				978
Income taxes payable			1,329				-
Other accruals			1,668				1,669
Total current liabilities			29,184				39,471
OTHER LONG-TERM LIABILITIES			1,052				1,215
DEFERRED INCOME TAXES			7,791				7,876
Total liabilities			38,027				48,562
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Common stock, par value $0.05; 10,334,280 shares issued and outstanding as of January 1, 2012 and 10,307,177 shares issued and outstanding as of April 3, 2011			517				515
Additional paid-in capital			42,512				41,060
Retained earnings			110,870				95,013
Accumulated other comprehensive income (loss)			(271)				(145)
Total shareholders’ equity			153,628				136,443
		$	191,655			$	185,005

See accompanying notes to financial statements.

 

 

3

 

 

---

Table of Contents

HAWKINS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

 

			000000000000				000000000000				000000000000				000000000000
		Three Months Ended								Nine Months Ended
(In thousands, except share and per-share data)		January 1,				December 31,				January 1,				December 31,
		2012				2010				2012				2010
Sales		$	84,160			$	70,620			$	260,624			$	215,684
Cost of sales			(68,481)				(56,894)				(208,268)				(165,768)
Gross profit			15,679				13,726				52,356				49,916
Selling, general and administrative expenses			(7,163)				(6,893)				(22,864)				(20,368)
Operating income			8,516				6,833				29,492				29,548
Investment income			26				71				119				272
Income from continuing operations before income taxes			8,542				6,904				29,611				29,820
Provision for income taxes			(3,257)				(2,650)				(11,255)				(11,397)
Income from continuing operations			5,285				4,254				18,356				18,423
Income from discontinued operations, net of tax			267				-				824				-
Net income		$	5,552			$	4,254			$	19,180			$	18,423
Weighted average number of shares outstanding-basic			10,332,480				10,259,458				10,320,810				10,256,674
Weighted average number of shares outstanding-diluted			10,410,533				10,355,888				10,403,711				10,336,169
Basic earnings per share
Earnings per share from continuing operations		$	0.51			$	0.41			$	1.78			$	1.80
Earnings per share from discontinued operations			0.03				-				0.08				-
Basic earnings per share		$	0.54			$	0.41			$	1.86			$	1.80
Diluted earnings per share
Earnings per share from continuing operations		$	0.51			$	0.41			$	1.76			$	1.78
Earnings per share from discontinued operations			0.02				-				0.08				-
Diluted earnings per share		$	0.53			$	0.41			$	1.84			$	1.78
Cash dividends declared per common share		$	-			$	-			$	0.32			$	0.40

See accompanying notes to financial statements.

 

4

 

 

---

Table of Contents

HAWKINS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 

			December 31,				December 31,
		Nine Months Ended
(In thousands)		January 1, 2012				December 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	19,180			$	18,423
Reconciliation to cash flows:
Depreciation and amortization			6,238				5,106
Deferred income taxes			-				333
Stock compensation expense			945				1,132
Loss (gain) from property disposals			(17)				(32)
Changes in operating accounts providing (using) cash:
Trade receivables			354				(2,015)
Inventories			(3,414)				(3,087)
Accounts payable			(5,616)				1,437
Accrued liabilities			(1,203)				(2,406)
Income taxes			3,526				4,882
Other			462				538
Net cash provided by operating activities			20,455				24,311
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant, and equipment			(13,827)				(7,764)
Purchases of investments			(10,735)				(4,410)
Sale and maturities of investments			11,840				23,930
Acquisition of Vertex			(1,709)				-
Proceeds from property disposals			224				80
Net cash provided by (used in) investing activities			(14,207)				11,836
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends paid			(6,417)				(7,005)
Proceeds from the exercise of stock options			190				-
Excess tax benefit from share-based compensation			76				-
Proceeds from the sale of stock under the employee stock purchase plan			243				-
Net cash used in financing activities			(5,908)				(7,005)
NET INCREASE IN CASH AND CASH EQUIVALENTS			340				29,142
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD			18,940				18,772
CASH AND CASH EQUIVALENTS, END OF PERIOD		$	19,280			$	47,914
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for income taxes		$	8,158			$	6,181
Noncash investing activities- Capital expenditures in accounts payable		$	1,103			$	254

See accompanying notes to financial statements.

 

5

 

 

---

Table of Contents

HAWKINS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1 – Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions for Form 10-Q and, accordingly, do not include all information and footnotes required by generally accepted accounting principles for complete financial statements. These statements should be read in conjunction with the financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended April 3, 2011, previously filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly our financial position and the results of our operations and cash flows for the periods presented. All adjustments made to the interim financial statements were of a normal recurring nature.

The accounting policies we follow are set forth in “Item 8. Financial Statements and Supplementary Data, Note 1 – Nature of Business and Significant Accounting Policies” to our financial statements in our Annual Report on Form 10-K for the fiscal year ended April 3, 2011 (“fiscal 2011”) filed with the SEC on June 9, 2011.

At the beginning of the current fiscal year ending April 1, 2012 (“fiscal 2012”), we changed our quarterly reporting to a 13 week convention.

The results of operations for the period ended January 1, 2012 are not necessarily indicative of the results that may be expected for the full year. During the fourth quarter of fiscal 2011 we acquired substantially all of the assets of Vertex Chemical Corporation, Novel Wash Co. Inc. and R.H.A. Corporation, (collectively, “Vertex”). Vertex’s results are incorporated in the consolidated financial statements from the date of acquisition. See Note 11 – Business Combinations for additional information.

Note 2 – Earnings per Share

Basic earnings per share (“EPS”) are computed by dividing net earnings by the weighted-average number of common shares outstanding. Diluted EPS includes the incremental shares assumed to be issued upon the exercise of stock options and the incremental shares assumed to be issued as performance units and restricted stock. Basic and diluted EPS were calculated using the following:

 

		Three months ended								Nine months ended
		January 1,				December 31,				January 1,				December 31,
		2012				2010				2012				2010
Weighted-average common shares outstanding – basic			10,332,480				10,259,458				10,320,810				10,256,674
Dilutive impact of stock options, performance units, and restricted stock			78,053				96,430				82,901				79,495
Weighted-average common shares outstanding - diluted			10,410,533				10,355,888				10,403,711				10,336,169

For the periods ended January 1, 2012 and December 31, 2010, there were no shares or stock options excluded from the calculation of weighted-average common shares for diluted EPS.

Note 3 – Discontinued Operations

In February 2009, we agreed to sell our inventory and entered into a marketing agreement regarding the business of our Pharmaceutical segment, which provided pharmaceutical chemicals to retail pharmacies and small-scale pharmaceutical manufacturers. The agreement provides for annual payments based on a percentage of gross profit on future sales up to a maximum of approximately $3.7 million. We have no significant remaining obligations to fulfill under the agreement. To date we have received $2.2 million under this agreement and have recorded gains of approximately $1.3 million before taxes in fiscal 2012. The results of the Pharmaceutical segment have been reported as discontinued operations for all periods presented.

 

6

 

 

---

Table of Contents

Note 4 – Cash and Cash Equivalents and Investments

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

 

Description		January 1,
(In thousands)		2012				Level 1				Level 2				Level 3
Assets:
Cash			$            18,744				$     18,744				$                -				$                -
Certificates of deposit			17,336				-				17,336				-
Money market securities			535				535				-				-
Description		April 3,
(In thousands)		2011				Level 1				Level 2				Level 3
Assets:
Cash			$            18,485				$    18,485				$                -				$                -
Certificates of deposit			18,461				-				18,461				-
Money market securities			455				455				-				-

Our financial assets that are measured at fair value on a recurring basis are certificates of deposit (“CD’s”), with maturities ranging from three months to two years which fall within valuation technique Level 2. The CD’s are classified as investments in current assets and noncurrent assets on the Condensed Consolidated Balance Sheets. As of January 1, 2012, the CD’s in current assets had a fair value of $11.0 million, and in noncurrent assets, the CD’s had a fair value of $6.3 million.

The carrying value of cash and cash equivalents accounts approximates fair value, as maturities are three months or less. We did not have any financial liability instruments subject to recurring fair value measurements as of January 1, 2012.

Note 5 – Inventories

Inventories at January 1, 2012 and April 3, 2011 consisted of the following:

 

		January 1,				April 3,
		2012				2011
(In thousands)
Finished goods (FIFO basis)			$          38,048				$          35,071
LIFO reserve			(5,681)				(5,854)
Net inventory			$          32,367				$          29,217

The first in, first out (“FIFO”) value of inventories accounted for under the last in, first out (“LIFO”) method was $32.0 million at January 1, 2012 and $28.6 million at April 3, 2011. The remainder of the inventory was valued and accounted for under the FIFO method.

The LIFO reserve decreased $0.6 million during the three months ended January 1, 2012 compared to an increase of $0.6 million the three months ended December 31, 2010. During the nine months ended January 1, 2012, the LIFO reserve decreased $0.2 million while the reserve increased $1.4 million in the nine months ended December 31, 2010 as a result of the changes in projected fiscal year-end inventory costs, inventory product mix and inventory volumes. The valuation of LIFO inventory for interim periods is based on our estimates of year-end inventory levels and costs.

 

7

 

 

---

Table of Contents

Note 6 – Goodwill and Intangible Assets

The carrying amount of goodwill as of January 1, 2012 was $6.5 million and at April 3, 2011 was $6.2 million.

The $0.3 million increase in goodwill relates to the finalization of the determination of the fair value of inventory acquired as part of the acquisition of Vertex.

Intangible assets consist primarily of customer lists, trade secrets and non-compete agreements classified as finite life and trademarks and trade names classified as indefinite life, related to previous business acquisitions. A summary of our intangible assets as of January 1, 2012 and April 3, 2011 were as follows:

 

		January 1, 2012
		Gross Carrying Amount				Accumulated Amortization				Net
(In thousands)
Finite-life intangible assets
Customer relationships			$                5,508				$                (637)				$                4,871
Trademark			1,240				(119)				1,121
Trade secrets			862				(494)				368
Carrier relationships			800				(77)				723
Other finite-life intangible assets			339				(308)				31
Total finite-life intangible assets			8,749				(1,635)				7,114
Indefinite-life intangible assets			1,227				-				1,227
Total intangible assets, net			$                9,976				$                (1,635)				$                8,341
		April 3, 2011
		Gross Carrying Amount				Accumulated Amortization				Net
(In thousands)
Finite-life intangible assets
Customer relationships			$                5,508				$                (423)				$                5,085
Trademark			1,240				(26)				1,214
Trade secrets			862				(413)				449
Carrier relationships			800				(18)				782
Other finite-life intangible assets			339				(285)				54
Total finite-life intangible assets			8,749				(1,165)				7,584
Indefinite-life intangible assets			1,227				-				1,227
Total intangible assets, net			$                9,976				$                (1,165)				$                8,811

Note 7 – Income Taxes

In the preparation of our financial statements, management calculates income taxes based upon the estimated effective rate applicable to operating results for the full fiscal year. This includes estimating the current tax liability as well as assessing differences resulting from different treatment of items for tax and book accounting purposes. These differences result in deferred tax assets and liabilities, which are recorded on the balance sheet. These assets and liabilities are analyzed regularly and management assesses the likelihood that deferred tax assets will be recovered from future taxable income. We record any interest and penalties related to income taxes as income tax expense in the statements of income.

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

 

8

 

 

---

Table of Contents

Note 8 – Accumulated Other Comprehensive Income (Loss)

Components of accumulated other comprehensive income (loss) were as follows:

 

		January 1,				April 3,
(In thousands)		2012				2011
Unrealized gain (loss) on:
Available-for-sale investments		$	(8	)		$	3
Post-retirement plan liability adjustments			(263	)			(148	)
Accumulated other comprehensive loss		$	(271	)		$	(145	)

Note 9 – Stock Based Compensation

Stock Option Awards. The following table represents the stock option activity for the nine months ended January 1, 2012:

 

		Outstanding								Exercisable
		Shares				Weighted-     Average Exercise Price				Shares				Weighted- Average Exercise Price
Outstanding at beginning of period			131,997			$	17.82				66,666			$	17.67
Granted			-				-				-				-
Vested			-				-				27,999				15.43
Exercised			(12,333	)			15.43				(12,333	)			15.43
Forfeited or expired			-				-				-				-
Outstanding at end of period			119,664			$	18.07				82,332			$	17.24

Compensation expense for the three and nine months ended January 1, 2012 and December 31, 2010 related to stock options was not material.

Performance-Based Restricted Stock Units. Our Board of Directors approved a performance-based equity compensation arrangement for our executive officers during the first quarters of each of fiscal 2011 and 2012. These performance-based arrangements provide for the grant of performance-based restricted stock units that represent a possible future issuance of restricted shares of our common stock based on our pre-tax income target for the applicable fiscal year. The actual number of restricted shares to be issued to each executive officer will be determined when our final financial information becomes available after the applicable fiscal year and will be between zero shares and 45,081 shares in the aggregate for fiscal 2012. The restricted shares issued will fully vest two years after the last day of the fiscal year on which the performance is based. We are recording the compensation expense for the outstanding performance share units and then-converted restricted stock over the life of the awards.

The following table represents the restricted stock activity for the nine months ended January 1, 2012:

 

		Shares				Weighted- Average Grant   Date Fair Value
Outstanding at beginning of period			11,667			$	25.81
Granted			33,321				35.39
Vested			-				-
Forfeited or expired			-				-
Outstanding at end of period			44,988			$	32.91

We recorded compensation expense of $0.2 million and $0.6 million related to performance share units for the three and nine months ended January 1, 2012, respectively. We recorded compensation expense of $0.4 million and $0.9 million related to performance share units for the three and nine months ended December 31, 2010, respectively. Substantially all of the compensation expense was recorded in Selling, general and administrative expenses in the Condensed Consolidated Statements of Income.

 

9

 

 

---

Table of Contents

Restricted Stock Awards. As part of their retainer, each non-employee Director receives an annual grant of restricted stock for their Board services. The restricted stock awards are expensed over the requisite vesting period, which is one year from the date of issuance, based on the market value on the date of grant. The following table represents the Board’s restricted stock activity for the nine months ended January 1, 2012:

 

			Date Fair Value				Date Fair Value
		Shares				Weighted- Average Grant Date Fair Value
Outstanding at beginning of period			6,996			$	30.00
Granted			6,120				34.31
Vested			(6,996)				30.00
Forfeited or expired			-				-
Outstanding at end of period			6,120			$	34.31

Compensation expense for the quarter ended January 1, 2012 related to restricted stock awards to the Board was $0.1 million. Compensation expense for the quarter ended December 31, 2010 was not material. We recorded $0.2 million in compensation expense related to restricted stock awards to the Board for the nine month period ended January 1, 2012 and $0.1 million for the nine month period ended December 31, 2010.

Note 10 – Commitments and Contingencies

Litigation —On November 3, 2009, ICL Performance Products, LP (“ICL”), a chemical supplier to us, filed a lawsuit in the United States District Court for the Eastern District of Missouri, asserting breach of a contract for the sale of phosphoric acid in 2009 (the “2009 Contract”). ICL seeks to recover $7.3 million in damages and pre-judgment interest, and additionally seeks to recover its costs and attorneys’ fees. ICL also claimed that we breached a contract for the sale of phosphoric acid in 2008 (the “2008 Contract”). ICL has since dropped its claim for breach of the 2008 Contract. We have counterclaimed against ICL alleging that ICL falsely claimed to have a shortage of raw materials that prevented it from supplying us with the contracted quantity of phosphoric acid for 2008. We claim that ICL used this alleged shortage and the threat of discontinued shipments of phosphoric acid to force us to pay increased prices for the remainder of 2008, and to sign the 2009 Contract. Based on this alleged conduct, we have brought four alternate causes of action including: (1) breach of contract, (2) breach of the implied covenant of good faith and fair dealing, (3) negligent misrepresentation, and (4) intentional misrepresentation. We seek to recover $1.5 million in damages, and additionally seek to recover punitive damages, pre- and post-judgment interest, and our costs and attorneys’ fees. The discovery phase in this action is complete, and both parties have moved for summary judgment in their favor. We do not know how or when the Court might rule on the parties’ summary judgment motions. No trial date has been set. We are not able to predict the ultimate outcome of this litigation, but it may be costly and disruptive. Lawsuits such as this can result in substantial costs and divert our management’s attention and resources, which may have a material adverse effect on our business and results of operations, including cash flows.

We are a party from time to time in other legal proceedings arising in the ordinary course of our business. To date, none of the litigation has had a material effect on us.

Note 11 – Business Combinations

On January 14, 2011, we completed the acquisition of the assets of Vertex for $27.2 million with $25.5 million paid at closing and the remaining $1.7 million paid during the first quarter of fiscal 2012. We acquired substantially all of the assets used in Vertex’s business, which is primarily the manufacture and distribution of sodium hypochlorite and the distribution of caustic soda, hydrochloric acid and related products.

Vertex operating results are included in our Condensed Consolidated Statements of Income in our Industrial segment from the date of acquisition.

 

 

10

 

 

---

Table of Contents

The following unaudited pro forma condensed consolidated financial results of operations are presented as if the Vertex acquisition had been completed at the beginning of the each period presented:

 

		Three months ended								Nine months ended
		January 1,				December 31,				January 1,				December 31,
(In thousands, except share and per-share data)		2012				2010				2012				2010
Pro forma net sales		$	84,160			$	79,920			$	260,624			$	245,977
Pro forma net earnings			5,552				4,533				19,180				19,799
Pro forma earnings per share:
Basic		$	0.54			$	0.44			$	1.86			$	1.93
Diluted			0.53				0.44				1.84				1.92
Weighted average common shares outstanding:
Basic			10,332,480				10,259,458				10,320,810				10,256,674
Diluted			10,410,533				10,355,888				10,403,711				10,336,169

The results for the three and nine months ended January 1, 2012 shown in this table reflect actual condensed consolidated financial results for the period, while the results for the three and nine months ended December 31, 2010 reflect pro forma condensed consolidated financial results. These unaudited financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of each fiscal period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the acquisition.

Note 12 – Segment Information

We have two reportable segments: Industrial and Water Treatment. The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in our fiscal 2011 Annual Report on Form 10-K. Product costs and expenses for each segment are based on actual costs incurred along with cost allocation of shared and centralized functions. We evaluate performance based on profit or loss from operations before income taxes not including nonrecurring gains and losses. Reportable segments are defined by product and type of customer. Segments are responsible for the sales, marketing and development of their products and services. The segments do not have separate accounting, administration, customer service or purchasing functions. There are no intersegment sales and no operating segments have been aggregated. Given our nature, it is not practical to disclose revenues from external customers for each product or each group of similar products. No single customer represents 10 percent or more of our revenue. Sales are primarily within the United States and all assets are located within the United States.

 

Reportable Segments		Industrial				Water     Treatment				Total
(In thousands)
Three months ended January 1, 2012:
Sales		$	63,741			$	20,419			$	84,160
Gross profit			10,213				5,466				15,679
Operating income			5,716				2,800				8,516
Three months ended December 31, 2010:
Sales		$	51,282			$	19,338			$	70,620
Gross profit			8,627				5,099				13,726
Operating income			4,130				2,703				6,833
Nine months ended January 1, 2012:
Sales		$	188,646			$	71,978			$	260,624
Gross profit			31,786				20,570				52,356
Operating income			17,143				12,349				29,492
Nine months ended December 31, 2010:
Sales		$	146,016			$	69,668			$	215,684
Gross profit			28,550				21,366				49,916
Operating income			15,894				13,654				29,548

 

11

 

 

---

Table of Contents

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a discussion and analysis of our financial condition and results of operations for the three and nine months ended January 1, 2012 as compared to December 31, 2010. This discussion should be read in conjunction with the Condensed Financial Statements and Notes to Condensed Financial Statements included in this Form 10-Q and Item 8 of our Annual Report on Form 10-K for the fiscal year ended April 3, 2011 (“fiscal 2011”). References to fiscal 2012 refer to the fiscal year ending April 1, 2012.

Overview

We derive substantially all of our revenues from the sale of bulk and specialty chemicals to our customers in a wide variety of industries. We began our operations primarily as a distributor of bulk chemicals with a strong customer focus. Over the years we have maintained our strong customer focus and have expanded our business by increasing our sales of value-added specialty chemical products, including repackaging, blending and manufacturing certain products. In recent years, we significantly expanded the sales of our higher-margin blended and manufactured products. We expect this specialty chemical portion of our business to continue to grow.

During the third quarter of fiscal 2012, we completed the purchase of a 28-acre parcel of land in Rosemount, Minnesota. We began construction of a new facility on the site during the quarter and expect it to be operational in late calendar 2012. The site provides capacity for future business growth and lessens our dependence on our flood-prone sites on the Mississippi River. While we expect to transfer some blending and manufacturing activity to the Rosemount site, we do not intend to close any sites we currently operate.

In the fourth quarter of fiscal 2011, we completed the acquisition of substantially all of the assets of Vertex, a manufacturer of sodium hypochlorite in the central Midwest. In addition to the manufacture of sodium hypochlorite bleaches, Vertex distributes and provides terminal services for bulk liquid inorganic chemicals, and contract and private label packaging for household chemicals. Its corporate headquarters are located in St. Louis, Missouri, with manufacturing sites in Dupo, Illinois, Camanche, Iowa, and Memphis, Tennessee. In connection with the acquisition we paid the sellers $27.2 million and assumed certain liabilities of Vertex. Vertex’s business is part of our Industrial Group.

We seek to maintain relatively constant gross profit dollars on each of our products as the cost of our raw materials increase or decrease. Since we expect that we will continue to experience fluctuations in our raw material costs and resulting prices in the future, we believe that gross profit dollars is the best measure of our profitability from the sale of our products. If we maintain relatively stable profit dollars on each of our products, our reported gross profit percentage will decrease when the cost of the product increases and will increase when the cost of the product decreases.

We use the last in, first out (“LIFO”) method for valuing substantially all of our inventory, which causes the most recent product costs to be recognized in our income statement. The valuation of LIFO inventory for interim periods is based on our estimates of fiscal year-end inventory levels and costs. The LIFO inventory valuation method and the resulting cost of sales are consistent with our business practices of pricing to current commodity chemical raw material prices. We recorded a $0.6 million decrease in our LIFO reserve for the three months ended January 1, 2012 and a $0.2 million decrease in our LIFO reserve for the nine months ended January 1, 2012, which increased our reported gross profit by those amounts in those periods. While we experienced rising commodity chemical costs during the first nine months of fiscal 2012, we anticipate certain commodity chemical costs to decline through the remainder of the fiscal year. We are also projecting lower inventory volumes at the end of fiscal 2012 when compared to the end of fiscal 2011. We recorded a $0.6 million increase in our LIFO reserve for the three months ended December 31, 2010 and a $1.4 million increase in our LIFO reserve for the nine months ended December 31, 2010, which decreased our gross profit by that amount in those periods.

 

12

 

 

---

Table of Contents

Results of Operations

The following table sets forth the percentage relationship of certain items to sales for the period indicated:

 

		Three months ended								Nine months ended
		Jan 1				Dec 31				Jan 1				Dec 31
		2012				2010				2012				2010
Sales			100.0	%			100.0	%			100.0	%			100.0	%
Cost of sales			(81.4)				(80.6)				(79.9)				(76.9)
Gross profit			18.6				19.4				20.1				23.1
Selling, general and administrative expenses			(8.5)				(9.8)				(8.8)				(9.4)
Operating income			10.1				9.7				11.3				13.7
Investment income			-				0.1				-				0.1
Income from continuing operations before income taxes			10.1				9.8				11.3				13.8
Provision for income taxes			(3.8)				(3.8)				(4.2)				(5.3)
Incoming from continuing operations			6.3				6.0				7.1				8.5
Income from discontinued operations, net of tax			0.3				-				0.3				-
Net income			6.6	%			6.0	%			7.4	%			8.5	%

Three Months Ended January 1, 2012 Compared to the Three Months Ended December 31, 2010

Sales

Sales increased $13.5 million, or 19.2%, to $84.2 million in the three months ended January 1, 2012 as compared to $70.6 million in the same period of the prior year. Sales of bulk chemicals, including caustic soda, were approximately 23% of sales during the three months ended January 1, 2012 as compared to 20% during the same period of the prior year. Vertex, which we acquired during the fourth quarter of fiscal 2011, contributed $9.3 million of the increase in sales during the third quarter of fiscal 2012. We experienced increased sales across the majority of our product lines in the third quarter of fiscal 2012 as compared to the same period in fiscal 2011.

Industrial Segment. Industrial segment sales increased $12.5 million, or 24.3%, to $63.7 million for the three months ended January 1, 2012 as compared to the same period of the prior year. Vertex contributed $9.3 million of the increase in sales during the third quarter of fiscal 2012. The remaining increase in sales was the result of higher selling prices across the majority of our product lines due to increased commodity chemical prices, partially offset by somewhat lower overall sales volumes.

Water Treatment Segment. Water Treatment segment sales increased $1.1 million, or 5.6%, to $20.4 million for the three months ended January 1, 2012 as compared to the same period of the prior year. The sales increase was primarily due to higher selling prices across the majority of our product lines, partially offset by somewhat lower bulk chemical sales volumes.

Gross Profit

Gross profit was $15.7 million, or 18.6% of sales, for the three months ended January 1, 2012, as compared to $13.7 million, or 19.4% of sales, for the same period of the prior year. The LIFO method of valuing inventory increased gross profit by $0.6 million for the three months ended January 1, 2012 whereas it decreased gross profit by $0.6 million for the three months ended December 31, 2010.

Industrial Segment. Gross profit for the Industrial segment was $10.2 million, or 16.0% of sales, for the three months ended January 1, 2012, as compared to $8.6 million, or 16.8% of sales, for the same period of the prior year. The increase in gross profit dollars resulted from the addition of the Vertex business to this segment, partially offset by competitive pricing pressures. The LIFO method of valuing inventory increased gross profit in this segment by $0.3 million for the three months ended January 1, 2012, while it decreased gross profit by $0.6 million for the three months ended December 31, 2010.

 

13

 

 

---

Table of Contents

Water Treatment Segment.  Gross profit for the Water Treatment segment was $5.5 million, or 26.8% of sales, for the three months ended January 1, 2012, as compared to $5.1 million, or 26.4% of sales, for the three months ended December 31, 2010. The increase in gross profit was primarily due to increased profits across certain product lines partially offset by higher operational and infrastructure costs compared to the prior year. The LIFO method of valuing inventory increased gross profit in this segment by $0.3 million for the three months ended January 1, 2012, while it had a negligible impact on gross profit for the three months ended December 31, 2010.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $7.2 million, or 8.5% of sales, for the three months ended January 1, 2012 as compared to $6.9 million, or 9.8% of sales, for the three months ended December 31, 2010. The increase was due to the addition of expenses related to the Vertex business, which we acquired during the fourth quarter of fiscal 2011, partially offset by lower equity and other incentive plan costs and costs in the prior year related to the Vertex acquisition.

Operating Income

Operating income was $8.5 million for the three months ended January 1, 2012 and $6.8 million for the three months ended December 31, 2010. The Industrial segment increased $1.6 million while the Water Treatment segment increased $0.1 million for the three months ended January 1, 2012, as compared to the same period of the prior year.

Investment Income

Investment income was negligible during the three months ended January 1, 2012 and $0.1 million for the three months ended December 31, 2010.

Provision for Income Taxes

Our effective income tax rate was 38.1% for the three months ended January 1, 2012, compared to 38.4% for the three months ended December 31, 2010. The effective tax rate is impacted by projected levels of taxable income, permanent items, and state taxes.

Nine Months Ended January 1, 2012 Compared to the Nine Months Ended December 31, 2010

Sales

Sales increased $44.9 million, or 20.8%, to $260.6 million in the nine months ended January 1, 2012 as compared to $215.7 million in the same period of the prior year. Sales of bulk chemicals, including caustic soda, were approximately 22% of sales during the nine months ended January 1, 2012 and 20% during the nine months ended December 31, 2010. Vertex, which we acquired during the fourth quarter of fiscal 2011, contributed $30.7 million of the increase in sales during the nine months ended January 1, 2012. We experienced higher selling prices due to increased commodity chemical prices, which was partially offset by lower bulk sales volumes in the nine months ended January 1, 2012 as compared to the nine months ended December 31, 2010.

Industrial Segment.  Industrial segment sales increased $42.6 million, or 29.2%, to $188.6 million for the nine months ended January 1, 2012 as compared to the same period of the prior year. Vertex contributed $30.7 million of the increase in sales during the nine months ended January 1, 2012. The remaining increase in sales was the result of higher selling prices across the majority of our product lines due to increased commodity chemical prices, partially offset by lower bulk chemical sales volumes.

Water Treatment Segment.  Water Treatment segment sales increased $2.3 million, or 3.3%, to $72.0 million for the nine months ended January 1, 2012 as compared to the same period of the prior year. The sales increase was primarily due to increased sales of manufactured and specialty chemical products partially offset by lower bulk chemical sales, with overall sales volumes negatively impacted by unfavorable weather conditions during the first half of the year.

Gross Profit

Gross profit was $52.4 million, or 20.1% of sales, for the nine months ended January 1, 2012, as compared to $49.9 million, or 23.1% of sales, for the nine months ended December 31, 2010. The LIFO method of valuing inventory increased gross profit by $0.2 million for the nine months ended January 1, 2012, and decreased gross profit by $1.4 million for the nine months ended December 31, 2010.

 

14

 

 

---

Table of Contents

Industrial Segment.  Gross profit for the Industrial segment was $31.8 million, or 16.8% of sales, for the nine months ended January 1, 2012, as compared to $28.5 million, or 19.6% of sales, for the nine months ended December 31, 2010. The increase in gross profit dollars resulted from the addition of the Vertex business to this segment, offset by competitive pricing pressures. The LIFO method of valuing inventory had a minimal impact on gross profit for the nine months ended January 1, 2012 and decreased gross profit in this segment by $1.3 million for the nine months ended December 31, 2010.

Water Treatment Segment.  Gross profit for the Water Treatment segment was $20.6 million, or 28.6% of sales, for the nine months ended January 1, 2012, as compared to $21.4 million, or 30.7% of sales, for the nine months ended December 31, 2010. The decrease in gross profit was primarily due to competitive pricing pressures and lowered sales volumes because of unfavorable weather conditions during the first half of fiscal 2012. The LIFO method of valuing inventory increased gross profit in this segment by $0.2 million for the nine months ended January 1, 2012 and decreased gross profit in this segment by $0.1 million for the nine months ended December 31, 2010.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $22.9 million, or 8.8% of sales, for the nine months ended January 1, 2012 as compared to $20.4 million, or 9.4% of sales, for the three months ended December 31, 2010. The increase was primarily due to the addition of expenses related to the Vertex business, which we acquired during the fourth quarter of fiscal 2011, partially offset by lower equity and other incentive plan costs and costs in the prior year related to the Vertex acquisition.

Operating Income

Operating income was $29.5 million for the nine months ended January 1, 2012 and the same period in the prior year. The Industrial segment increased $1.3 million and the Water Treatment segment decreased $1.3 million.

Investment Income

Investment income was $0.1 million for the nine months ended January 1, 2012 compared to $0.3 million for the nine months ended December 31, 2010.

Provision for Income Taxes

Our effective income tax rate was 38.0% for the nine months ended January 1, 2012, compared to 38.2% for the nine months ended December 31, 2010. The effective tax rate is impacted by projected levels of taxable income, permanent items, and state taxes.

Liquidity and Capital Resources

Cash provided by operating activities for the nine months ended January 1, 2012 was $20.5 million compared to $24.3 million for the nine months ended December 31, 2010. The decrease in cash provided by operating activities was due primarily to an increase in working capital balances, including the timing of inventory purchases and the related vendor payments, and the timing of income tax payments. Due to the nature of our operations, which includes purchases of large quantities of bulk chemicals, timing of purchases can result in significant changes in working capital investment and the resulting operating cash flow. Historically, our cash requirements increase during the period from April through November as caustic soda inventory levels increase as the majority of barges are received during this period. Additionally, due to the seasonality of the water treatment business, our accounts receivable balance generally increases during the period of April through September.

Cash and investments available-for-sale of $36.6 million at January 1, 2012 decreased by $0.8 million as compared with the $37.4 million available as of April 3, 2011, primarily due to cash flows generated from operations, offset by capital expenditures, dividends paid and $1.7 million disbursed for the acquisition of Vertex.

 

15

 

 

---

Table of Contents

Capital Expenditures

Capital expenditures were $13.8 million for the nine months ended January 1, 2012 compared to $7.8 million in the same period in the prior fiscal year. Significant capital expenditures during the nine months ended January 1, 2012 consisted of approximately $4.8 million related to site acquisition costs and the construction of our new facility in Rosemount, Minnesota, $3.5 million for business expansion and process improvement projects, $1.7 million for other facility, regulatory and safety improvements and $0.5 million for new and replacement route sales trucks for the Water Treatment segment. We expect cash balances and our cash flows from operations will be sufficient to fund our planned capital expenditures for the remainder of fiscal 2012.

Critical Accounting Policies

Our significant accounting policies are set forth in Note 1 to our financial statements in our Annual Report on Form 10-K for the fiscal year ended April 3, 2011. The accounting policies used in preparing our interim fiscal 2011 financial statements are the same as those described in our Annual Report.

Forward-Looking Statements

The information presented in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts, but rather are based on our current expectations, estimates and projections, and our beliefs and assumptions. We intend words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will” and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. These factors could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Additional information concerning potential factors that could affect future financial results is included in our Annual Report on Form 10-K for the fiscal year ended April 3, 2011. We caution you not to place undue reliance on these forward-looking statements, which reflect our management’s view only as of the date of this Quarterly Report on Form 10-Q. We are not obligated to update these statements or publicly release the result of any revisions to them to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At January 1, 2012, our investment portfolio included $17.3 million of certificates of deposit classified as fixed income securities and cash and cash equivalents of $19.3 million. The fixed income securities, like all fixed income instruments, are subject to interest rate risks and will decline in value if market interest rates increase. However, while the value of the investment may fluctuate in any given period, we intend to hold our fixed income investments until recovery. Consequently, we would not expect to recognize an adverse impact on net income or cash flows during the holding period. We adjust the carrying value of our investments if impairment occurs that is other than temporary.

We are subject to the risk inherent in the cyclical nature of commodity chemical prices. However, we do not currently purchase forward contracts or otherwise engage in hedging activities with respect to the purchase of commodity chemicals. We attempt to pass changes in material prices on to our customers, however, there are no assurances that we will be able to pass on cost increases in the future as our pricing must be competitive.

 

16

 

 

---

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under supervision and with the participation of management, including the chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Exchange Act. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective. Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control

There was no change in our internal control over financial reporting during the third quarter of fiscal 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On November 3, 2009, ICL Performance Products, LP (“ICL”), a chemical supplier to us, filed a lawsuit in the United States District Court for the Eastern District of Missouri, asserting breach of a contract for the sale of phosphoric acid in 2009 (the “2009 Contract”). ICL seeks to recover $7.3 million in damages and pre-judgment interest, and additionally seeks to recover its costs and attorneys’ fees. ICL also claimed that we breached a contract for the sale of phosphoric acid in 2008 (the “2008 Contract”). ICL has since dropped its claim for breach of the 2008 Contract. We have counterclaimed against ICL alleging that ICL falsely claimed to have a shortage of raw materials that prevented it from supplying us with the contracted quantity of phosphoric acid for 2008. We claim that ICL used this alleged shortage and the threat of discontinued shipments of phosphoric acid to force us to pay increased prices for the remainder of 2008, and to sign the 2009 Contract. Based on this alleged conduct, we have brought four alternate causes of action including: (1) breach of contract, (2) breach of the implied covenant of good faith and fair dealing, (3) negligent misrepresentation, and (4) intentional misrepresentation. We seek to recover $1.5 million in damages, and additionally seek to recover punitive damages, pre- and post-judgment interest, and our costs and attorneys’ fees. The discovery phase in this action is complete, and both parties have moved for summary judgment in their favor. We do not know how or when the Court might rule on the parties’ summary judgment motions. No trial date has been set. We are not able to predict the ultimate outcome of this litigation, but legal proceedings such as this can result in substantial costs and divert our management’s attention and resources, which may have a material adverse effect on our business and results of operations, including cash flows.

We are a party from time to time in other legal proceedings arising in the ordinary course of our business. To date, none of the litigation has had a material effect on us.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended April 3, 2011.

 

17

 

 

---

Table of Contents

ITEM 6. EXHIBITS

 

 

 

(1)

Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2010, filed on July 29, 2010.

(2)

Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K dated October 28, 2009 and filed November 3, 2009.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: February 2, 2012

 

18

 

 

---

Table of Contents

				Exhibit Index
Exhibit				Description		Method of Filing
	3.1			Amended and Restated Articles of Incorporation.		Incorporated by Reference
	3.2			Amended and Restated By-Laws.		Incorporated by Reference
	31.1			Certification by Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act.		Filed Electronically
	31.2			Certification by Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act.		Filed Electronically
	32.1			Section 1350 Certification by Chief Executive Officer.		Filed Electronically
	32.2			Section 1350 Certification by Chief Financial Officer.		Filed Electronically
	101			Financial statements from the Quarterly Report on Form 10-Q of Hawkins, Inc. for the period ended January 1, 2012, filed with the SEC on February 2, 2012, formatted in Extensible Business Reporting Language (XBRL); (i) the Condensed Consolidated Balance Sheets at January 1, 2012 and December 31, 2010, (ii) the Condensed Consolidated Statements of Income for the Three and Nine Months Ended January 1, 2012 and December 31, 2010, (iii) the Condensed Consolidated Statements of Cash Flows for the Nine Months Ended January 1, 2012 and December 31, 2010, and (iv) Notes to Condensed Consolidated Financial Statements.		Filed Electronically

 

 

19